EcoDrugPlus

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSHHUG00000001988
Gene Symbol: HTR1F
2 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSHHUG00000035400
Gene Symbol: HTR2A
1 Cross references
212 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSHHUG00000031509
Gene Symbol: HTR2A
1 Cross references
213 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c

Ensembl ID : ENSHHUG00000030585
Gene Symbol: HTR2C
1 Cross references
148 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSHHUG00000043507
Gene Symbol: HTR3A
1 Cross references
196 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSHHUG00000043580
Gene Symbol: HTR3B
1 Cross references
170 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSHHUG00000001025
Gene Symbol: HTR4
1 Cross references
146 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSHHUG00000033581
Gene Symbol: HTR4
1 Cross references
146 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSHHUG00000034218
Gene Symbol: HTR5A
2 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSHHUG00000050632
Gene Symbol: HTR5A
1 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSHHUG00000038190
Gene Symbol: HTR7
2 Cross references
147 Possible Orthologues:

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSHHUG00000047711
Gene Symbol: ARAF
1 Cross references
184 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).